Brief: Celyad Oncology Updates On Allogeneic CAR T Clinical Candidates And shRNA-Based Preclinical Concepts
21/07/2021 12:17
July 21 (Reuters) - CELYAD ONCOLOGY SA CYAD.BR :
* CELYAD ONCOLOGY PRESENTED ON TUESDAY UPDATES ON ALLOGENEIC
CAR T
CLINICAL CANDIDATES AND SHRNA-BASED PRECLINICAL CONCEPTS AT
RESEARCH & DEVELOPMENT DAY
* PHASE 1 IMMUNICY-1 TRIAL EVALUATING CYAD-211 IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM) SHOWED DOSE
DEPENDENT ENGRAFTMENT UP TO DOSE LEVEL THREE (300×106 CELLS PER
INFUSION) WITH NO GRAFT-VERSUS-HOST DISEASE REPORTED TO DATE
* SUBMISSION OF IND APPLICATION FOR CYAD-203, A NEW
FIRST-IN-CLASS
SHRNA-BASED ALLOGENEIC, IL-18-ARMORED CAR T CANDIDATE, EXPECTED
IN MID-2022
* CYAD-101 FOLLOWING FOLFIRI PRECONDITIONING IN ADVANCED
METASTATIC COLORECTAL CANCER (MCRC) WAS WELL-TOLERATED; CELL
KINETIC AND ACTIVITY OF ALLOSHRINK TRIAL SUPPORT INITIATION OF
KEYNOTE-B79 PHASE 1B TRIAL OF CYAD-101 FOLLOWING FOLFOX
PRECONDITIONING CHEMOTHERAPY DURING EARLY Q4 2021
* ADDITIONAL CLINICAL ACTIVITY DATA FOR PHASE 1 IMMUNICY-1
TRIAL
OF CYAD-211 FOR R/R MM EXPECTED DURING H2 2021
* STUDY INITIATION FOR KEYNOTE-B79 PHASE 1B EXPECTED EARLY
Q4 2021
* SUBMISSION OF AN IND APPLICATION FOR CYAD-203 EXPECTED IN
MID-2022
* REPORT ADDITIONAL DATA FROM DOSE-ESCALATION PHASE 1
CYCLE-1
TRIAL EVALUATING CYAD-02 IN RELAPSED/REFRACTORY ACUTE MYELOID
LEUKEMIA AND MYELODYSPLASTIC SYNDROME IN MID-2021
Source text for Eikon: urn:newsml:reuters.com:*:nGNX4FpvWM
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))